Lamellar Biomedical Closes £2.3 million Investment Round

Released: Friday 24th July 2015

Lamellar Biomedical Closes £2.3 million Investment Round

Bellshill, Glasgow, 24th July, 2015

For Immediate Release

Lamellar Biomedical, a privately held Scottish biotechnology company, has closed a £2.33 million equity capital investment round subscribed entirely by existing Shareholders. The round comprised a Rights Issue, which was oversubscribed, together with exercise of Warrants held by certain Shareholders.

Participating investors included funds managed by Invesco Asset Management Limited, the Scottish Investment Bank at Scottish Enterprise, Barwell Plc, members of TRI Cap and a number of other private investors.

The Company is developing patent-protected medical devices based on mimetics of extra-alveolar lamellar bodies. Diseases which may benefit from the application of mimetic lamellar bodies include Dry Mouth, Dry Eye and Cystic Fibrosis, all conditions poorly served by currently available medications.

The funding raised will be deployed to further develop the Class 3 medical devices, Visco-ease for Radiotherapy-Induced Xerostomia (RIX) and Lamell-eye for moderate to severe Dry Eye Disease (DED). The Company’s lead compound, LMS-611, is also being developed as a novel therapy for Cystic Fibrosis and has EU Orphan Drug status for this indication.

Later this year, a clinical study of Visco-ease for RIX will commence at the Beatson West of Scotland Cancer Centre. A clinical study of Lamell-eye for DED will follow at the Glasgow Caledonian University Vision Sciences Eye Clinic.

Kerry Sharp, head of Scottish Investment Bank, said: “We are very pleased to be investing in a company that is addressing significant public health needs and striving to improve the health of citizens on a truly global scale. Our investment will help Lamellar develop effective devices for the treatment of diseases that are currently underserved by existing medications.

We look forward to continuing to work with the Company to help realise its ambitious growth plans”.

More information is available at


Dr Alec McLean
Chief Executive Officer
Tel: 01698-748832

Dr Duncan Moore
Tel: 07785-971715


View all News